Science Explorer Back to mapMap
Discussion
Researcher · Russian Cancer Research Center NN Blokhin · Russia

Sergei Tjulandin

Sergei Tjulandin publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Surgery, on topics such as Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology and Testicular diseases and treatments.

ORCID 0000-0001-9807-2229 OpenAlex
World rank
#266,297
of 7,710,434 ranked researchers
Rank in Russia
#531
of 179,717
Works
347
Citations
28k
Citations per work
81.7
h-index
54
i10-index 96Top 3% in Oncology
Sergei Tjulandin

What does Sergei Tjulandin research?

Sergei Tjulandin's work is mostly in Medicine (62%), Biochemistry, Genetics and Molecular Biology (15%).

Health Sciences: 215 works · 62.0% of their workMedicine: 215 works · 62.0% of their workOncology: 96 works · 27.6% of their workPulmonary and Respiratory Medicine: 63 works · 18.1% of their workSurgery: 40 works · 11.5% of their workReproductive Medicine: 17 works · 4.8% of their workEverything else: 81 works · 23.3% of their workLife Sciences: 51 works · 14.7% of their workBiochemistry, Genetics and Molecular Biology: 51 works · 14.7% of their workCancer Research: 27 works · 7.9% of their workMolecular Biology: 24 works · 6.8% of their workTHEIR WORKSergei Tjulandin347works
Life Sciences15%Health Sciences62%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine21562.0%
  2. Everything else8123.3%
    1. Biochemistry, Genetics and Molecular Biology5114.7%
  1. 1Oncology28% of their works
  2. 2Pulmonary and Respiratory Medicine18% of their works
  3. 3Surgery12% of their works
  4. 4Cancer Research8% of their works
  5. 5Molecular Biology7% of their works
  6. 6Reproductive Medicine5% of their works

Research topics

Which keywords describe Sergei Tjulandin's research?

The keywords of their largest research topics: Chemotherapy, Clinical Trials, Targeted Therapy, Cetuximab, KRAS Mutations, Chemotherapy-Induced Peripheral Neuropathy, Taxanes and Germ Cell Tumors.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 19 words, with their numbers
  1. Chemotherapy2065 topics
  2. Clinical Trials732 topics
  3. Targeted Therapy682 topics
  4. Cetuximab611 topic
  5. KRAS Mutations611 topic
  6. Chemotherapy-Induced Peripheral Neuropathy441 topic
  7. Taxanes441 topic
  8. Germ Cell Tumors411 topic
  9. Testicular Cancer411 topic
  10. Endoscopic Resection401 topic
  11. Gastric Cancer401 topic
  12. ALK Inhibitors381 topic
  13. EGFR Mutations381 topic
  14. Genomic Analysis351 topic
  15. Ovarian Cancer351 topic
  16. Cancer Genomics301 topic
  17. Mutational Signatures301 topic
  18. Breast Cancer291 topic
  19. HER2291 topic

Where does Sergei Tjulandin work?

Sergei Tjulandin's main affiliation in the publication record is Russian Cancer Research Center NN Blokhin, Russia.

How many publications and citations does Sergei Tjulandin have?

OpenAlex counts 347 works and 28,367 citations for Sergei Tjulandin, an h-index of 54, ranking #266,297 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Sergei Tjulandin. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.